글로벌 합성 API 시장 – 2023-2030

Global Synthetic API Market - 2023-2030

상품코드PH7772
발행기관DataM Intelligence
발행일2024.01.18
페이지 수185 Pages
포맷PDF + EXCEL
커버리지Global

6,525,00011,775,000

보고서 요약(국문)

개요
글로벌 합성 API 시장은 2022년 XX억 달러 규모에 도달했으며, 2023년부터 2030년까지 연평균 XX%의 성장률로 2030년에는 XX백만 달러에 이를 것으로 예상됩니다.
활성 성분은 질병의 진단, 치료, 완화, 예방에 생물학적 활성 또는 기타 직접적인 효과를 제공하거나 인체 구조 또는 기능에 영향을 미치는 모든 성분을 의미합니다.
합성 API 의약품은 일관성을 유지하고 오염 위험을 최소화하기 위해 엄격한 조건 하에서 제조됩니다. 활성 의약품 성분(API)의 등록은 복잡하고 매우 오랜 시간이 소요되며, 최종 의약품의 성공은 API의 품질과 성능에 크게 좌우됩니다.
시장 동향
만성 질환의 증가
만성 질환의 증가는 시장 성장의 중요한 동인입니다. 전 세계적으로 만성 질환 부담이 증가함에 따라 합성 API 제조업체의 시장 성장이 촉진되고 있습니다.

예를 들어, 미국 암 협회 보고서 2023에 따르면 미국에서는 약 1,958,310건의 새로운 암 발병 사례와 609,820명의 암 사망자가 발생할 것으로 예상됩니다. 전립선암 발병률은 지난 20년간 매년 3%씩 증가했습니다.
또한, 세계보건기구 보고서에 따르면 전 세계적으로 약 4억 2,200만 명이 당뇨병을 앓고 있으며, 이들 대부분은 저소득 및 중소득 국가에 거주하고 있고, 매년 150만 명이 당뇨병으로 직접 사망합니다. 당뇨병 발병 건수와 유병률은 지난 수십 년 동안 꾸준히 증가해 왔습니다.
더 나아가, 고령 인구 증가와 합성 API 제조 시설의 발전과 같은 주요 성장 동력이 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다.
의약품 가격 통제 정책
API의 높은 제조 비용은 시장 참여자들이 직면한 주요 과제 중 하나입니다. 제조업체는 cGMP와 같은 기준을 준수하기 위해 제조 시설 개선에 막대한 투자를 해야 하는 경우가 많습니다. 여기에는 생산 시설 개조, 자격 요건 및 프로세스 숙지, 규제 당국의 요구 사항을 충족하는 제품 효능 및 안전성 테스트 자료 구축 등이 포함됩니다.
소규모 생산 기업의 경우 규제 승인 획득 비용이 상대적으로 높습니다. 또한 API의 화학적 합성은 종종 고가의 희귀한 빌딩 블록과 원자재를 필요로 하므로 API 제조 비용이 더욱 증가합니다. 이러한 요인들이 예측 기간 동안 시장 성장을 저해하고 있습니다.
세그먼트 분석
글로벌 합성 API 시장은 유형, 제조업체 유형, 응용 분야 및 지역별로 세분화됩니다.
자체 API 제조업체 부문은 시장 점유율의 약 67.5%를 차지했습니다.
자체 API 제조업체 부문은 예측 기간 동안 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 이들은 의약품의 활성 물질 생산에 특화되어 있으며 고품질의 일관된 활성 성분을 생산함으로써 제약 산업에서 중요한 역할을 합니다.
예를 들어, 2023년 11월 Cadila Pharma는 Dahej에 API 제조 공장을 설립했습니다. 이 시설은 200억 루피(약 2억 2천만 달러)의 투자로 설립되었으며 최신 분산 제어 시스템(DCS) 자동화 기술을 갖추고 있습니다.
또한, 2023년 5월, 베링거인겔하임은 독일 본사에 임상 시험용 활성 의약품 원료(API) 및 의약품을 생산하는 3억 1,500만 달러 규모의 자체 공장을 설립했습니다.
그리고 2023년 11월, 루산파마는 약 300억 루피(약 3억 2천만 달러)를 투자하여 API 제조 시설을 가동했습니다. 따라서 이러한 요인들로 인해 해당 부문이 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.
지역 분석
북미는 세계 합성 API 시장에서 상당한 비중을 차지할 것으로 예상됩니다.
북미는 암, 당뇨병, 신경 질환과 같은 만성 질환의 유병률 증가 및 의료비 지출 증가와 같은 요인으로 인해 상당한 시장 점유율을 유지해 왔으며, 이러한 추세는 예측 기간 동안 지속될 것으로 예상됩니다.

예를 들어, 캐나다에서는 20세 이상 성인 약 240만 명이 허혈성 심장 질환 진단을 받았으며, 이 중 57만 8천 명은 심근경색 병력이 있습니다. 또한, 캐나다에서는 40세 이상 성인이 심부전 진단을 받고 있습니다.
또한, 2023년 1월, 유로핀스 CDMO 산하 알파라(Alphora Inc.)는 캐나다 온타리오주로 이전하여 API 개발 연구소를 확장했다고 발표했습니다. 더불어, 2023년 6월에는 에이펙스 랩스(Apex Labs Ltd.)가 미국에 있는 자사의 2차 환각제 API 공급업체에 대해 캐나다 보건부(Health Canada)의 승인을 획득했습니다.

COVID-19 영향 분석
COVID-19 팬데믹은 전 세계 합성 API 시장에 상당한 영향을 미쳤습니다. 2020년 초 팬데믹 발생으로 인해 광범위한 봉쇄와 제한 조치가 시행되었고, 이는 전 세계적으로 정기적인 진단, 치료, 제품 출시 및 상담에 영향을 미쳤습니다. 팬데믹 발생으로 인해 많은 제약 또는 의료기기 제조 업체들이 인력 부족에 직면했고, 봉쇄 조치로 인해 출근이 어려워졌습니다. 따라서 위와 같은 요인들로 인해 합성 API 시장은 예측 기간 동안 다소 영향을 받을 것으로 예상됩니다.
시장 세분화
유형별
• 혁신적인 합성 API
• 제네릭 합성 API
치료 분야별
• 자체 API 제조업체
• 상용 API 제조업체
적용 분야별
• 심장내과
• 호흡기내과
• 종양내과
• 안과
• 신경내과
• 정형외과
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
시장의 주요 글로벌 업체로는 Pfizer Inc., Sanofi SA, Boehringer Ingelheim, Bristol-Myers Squibb, AstraZeneca Plc, Viatris Inc., Teva Pharmaceutical Industries Ltd, BASF 등이 있습니다. SE, Dr Reddy's Laboratories Ltd, Merck & Co Inc 등이 주요 기업입니다.

주요 동향
• 2021년 3월, Piramal Pharma Ltd.는 인도의 주요 펩타이드 API 제조업체인 Hemmo Pharmaceuticals의 지분 100%를 인수했습니다.

• 2023년 9월, Celigo는 새로운 정책 관리 및 API 개발자 포털 지원을 추가하여 API 수명주기 전반을 지원하는 API 기능을 확장했습니다.

• 2023년 6월, API 제조업체 C2 PHARMA는 폴란드 제조 파트너인 Nobilus Ent.의 API인 디곡신에 대한 C-DMF 승인을 발표했습니다.

보고서 구매 이유

• 유형, 제조업체 유형, 응용 분야 및 지역별 글로벌 합성 API 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위해

• 트렌드 및 공동 개발 분석을 통해 상업적 기회를 식별하기 위해

• 모든 세그먼트를 포함한 글로벌 합성 API 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트

• PDF 보고서는 철저한 질적 인터뷰와 심층 연구를 바탕으로 한 종합적인 분석 자료로 구성되어 있습니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료는 엑셀 파일로 제공됩니다.
글로벌 합성 API 시장 보고서는 약 61개의 표, 59개의 그림, 그리고 185페이지 분량으로 구성됩니다.
주요 독자층 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Synthetic API Market reached US$ XX billion in 2022 and is expected to reach US$ XX million by 2030 growing at a CAGR of XX% during the forecast period 2023-2030.
An active ingredient is any ingredient that provides biologically active or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or affects the structure or any function of the body of human.
Synthetic API drugs are manufactured under stringent conditions to maintain consistency and minimize the risk of contamination. The registration of an active pharmaceutical ingredient (API) is complex and very time-consuming and the success of the final drug product strongly depends on the API's quality and performance.
Market Dynamics
Increasing prevalence of chronic diseases
The increasing prevalence of chronic diseases acts as a significant driver for market growth. The burden of chronic diseases is increasing worldwide which makes synthetic API manufacturers help to grow the market.
For instance, according to American Cancer Society Reports 2023, around 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. Cancer incidence increased for prostate cancer by 3% annually after two decades.
Also, according to the World Health Organization Report, about 422 million people worldwide have diabetes, the majority living in low-and middle-income countries, and 1.5 million deaths are directly attributed to diabetes each year. Both the number of cases and the prevalence of diabetes have been steadily increasing over the past few decades.
Furthermore, significant growth drivers such as the rising geriatric population, and advancements in synthetic API manufacturing units are expected to drive the market in the forecast period.
Drug price control policies
The high manufacturing cost of APIs is one of the major challenges faced by market players. Manufacturers often have to make costly investments for improvements in their manufacturing facilities to ensure compliance with standards such as the cGMP. This includes the renovation of production facilities, inculcating familiarity with qualification requirements and processes, and building a dossier of product efficacy and safety tests that meet the requirements of regulatory authorities.
The costs of obtaining regulatory approvals are relatively higher for firms with small volumes. The chemical synthesis of APIs also often requires expensive and uncommon building blocks and raw materials, which further adds to API manufacturing costs. These factors are hampering the growth of the market in the forecast period.
Segment Analysis
The global synthetic API market is segmented based on type, manufacturer type, application, and region.
The captive API manufacturer segment accounted for approximately 67.5% of the market share
The captive API manufacturer segment is expected to hold the largest market share over the period forecast. It is specialized in the production of active substances in pharmaceutical drugs and plays a crucial role in the pharmaceutical industry by producing high quality and consitent active ingredients.
For instance, in November 2023, Cadila Pharma launched an API manufacturing plant at Dahej. The facility is set up with an investment of Rs 200 crore and is equipped with the latest Distributed Control System (DCS) automation technology.
Additionally, in May 2023, Boehringer Ingelheim raised a $315 million in-house plant at its German headquarters that produces active pharmaceutical ingredients and drugs for clinical trials.
Also, in November 2023, Rusan Pharma launched the API manufacturing facility with an investment of around 300 crores. Hence, due to the above factors, the segment is expected to hold the largest market share.
Geographical Analysis
North America is expected to hold a significant position in the global synthetic API market share
North America has maintained a significant market proportion due to factors such as the rising prevalence of chronic diseases like cancer, diabetes, neurological disorders, and increasing healthcare expenditure, this trend is anticipated to continue throughout the forecast period.
For instance, in Canada, about 2.4 million Canadian adults aged 20 years and older live with diagnosed ischemic heart disease, including 578,000 with a history of a heart attack. Also, 40 years and older live with diagnosed heart failure in Canada.
Also, in January 2023, Eurofins CDMO Alphora Inc. declared that the company had moved to a new location in Ontario, Canada, and expanded its API development laboratory. Additionally, in June 2023, Apex Labs Ltd. secured Health Canada’s endorsement for its secondary US-based supplier of psilocybin Active Pharmaceutical Ingredient (API).
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the global synthetic API market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatment, product launches, and consultations worldwide. With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the synthetic API market is expected to be moderately affected over the forecast period.
Market Segmentation
By Type
• Innovative Synthetic API
• Generic Synthetic API
By Treatment
• Captive API Manufacturer
• Merchant API Manufacturer
By Application
• Cardiology
• Pulmonology
• Oncology
• Ophthalmology
• Neurology
• Orthopedic
• Other
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Pfizer Inc., Sanofi SA, Boehringer Ingelheim, Bristol-Myers Squibb, AstraZeneca Plc, Viatris Inc., Teva Pharmaceutical Industries Ltd, BASF SE, Dr Reddy's Laboratories Ltd, and Merck & Co Inc among others.
Key Developments
• In March 2021, Piramal Pharma Ltd. acquired a 100% Stake in Hemmo Pharmaceuticals which is a leading Indian manufacturer of peptide APIs.
• In September 2023, Celigo expanded the existing API Capabilities to support the full API lifecycle by adding new policy management and API developer portal support.
• In June 2023, API manufacturer C2 PHARMA declared the approval of a C-DMF for Digoxin, an API by the company's Polish manufacturing partner Nobilus Ent.
Why Purchase the Report?
• To visualize the global synthetic API market segmentation based on type, manufacturer type, application and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global synthetic API market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global synthetic API market report would provide approximately 61 tables, 59 figures, and 185 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Manufacturer Type
3.3. Snippet by Application
3.4. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing prevalence of chronic diseases
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Drug price control policies
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Innovative Synthetic API*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Generic Synthetic API
8. By Manufacturer Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturer Type
8.1.2. Market Attractiveness Index, By Manufacturer Type
8.2. Captive API Manufacturer *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Merchant API Manufacturer
9. By Application
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.1.2. Market Attractiveness Index, By Application
9.2. Cardiology*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Pulmonology
9.4. Oncology
9.5. Ophthalmology
9.6. Neurology
9.7. Orthopedic
9.8. Other
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturer Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturer Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturer Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturer Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturer Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Pfizer Inc.
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Sanofi SA
12.3. Boehringer Ingelheim
12.4. Bristol-Myers Squibb
12.5. AstraZeneca
12.6. Viatris Inc.
12.7. Teva Pharmaceutical Industries Ltd
12.8. BASF SE
12.9. Dr Reddy's Laboratories Ltd
12.10. Merck & Co Inc.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Pfizer Inc., 4. Key Developments, Sanofi SA, Boehringer Ingelheim, Bristol-Myers Squibb, AstraZeneca, Viatris Inc., Teva Pharmaceutical Industries Ltd, BASF SE, Dr Reddy's Laboratories Ltd, Merck & Co Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Synthetic API Market Value, By Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Synthetic API Market Value, By Manufracturer Type, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Synthetic API Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Synthetic API Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Synthetic API Market Value, By Type, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Synthetic API Market Value, By Type, 2022-2031 (US$ Million)

Table 7 Global Synthetic API Market Value, By Manufracturer Type, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Synthetic API Market Value, By Manufracturer Type, 2022-2031 (US$ Million)

Table 9 Global Synthetic API Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Synthetic API Market Value, By Application, 2022-2031 (US$ Million)

Table 11 Global Synthetic API Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Synthetic API Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Synthetic API Market Value, By Type, 2022-2031 (US$ Million)

Table 14 North America Synthetic API Market Value, By Manufracturer Type, 2022-2031 (US$ Million)

Table 15 North America Synthetic API Market Value, By Application, 2022-2031 (US$ Million)

Table 16 North America Synthetic API Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Synthetic API Market Value, By Type, 2022-2031 (US$ Million)

Table 18 South America Synthetic API Market Value, By Manufracturer Type, 2022-2031 (US$ Million)

Table 19 South America Synthetic API Market Value, By Application, 2022-2031 (US$ Million)

Table 20 South America Synthetic API Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Synthetic API Market Value, By Type, 2022-2031 (US$ Million)

Table 22 Europe Synthetic API Market Value, By Manufracturer Type, 2022-2031 (US$ Million)

Table 23 Europe Synthetic API Market Value, By Application, 2022-2031 (US$ Million)

Table 24 Europe Synthetic API Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Synthetic API Market Value, By Type, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Synthetic API Market Value, By Manufracturer Type, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Synthetic API Market Value, By Application, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Synthetic API Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East & Africa Synthetic API Market Value, By Type, 2022-2031 (US$ Million)

Table 30 Middle East & Africa Synthetic API Market Value, By Manufracturer Type, 2022-2031 (US$ Million)

Table 31 Middle East & Africa Synthetic API Market Value, By Application, 2022-2031 (US$ Million)

Table 32 Pfizer Inc.: Overview

Table 33 Pfizer Inc.: Product Portfolio

Table 34 Pfizer Inc.: Key Developments

Table 35 Sanofi SA: Overview

Table 36 Sanofi SA: Product Portfolio

Table 37 Sanofi SA: Key Developments

Table 38 Boehringer Ingelheim: Overview

Table 39 Boehringer Ingelheim: Product Portfolio

Table 40 Boehringer Ingelheim: Key Developments

Table 41 Bristol-Myers Squibb: Overview

Table 42 Bristol-Myers Squibb: Product Portfolio

Table 43 Bristol-Myers Squibb: Key Developments

Table 44 AstraZeneca : Overview

Table 45 AstraZeneca : Product Portfolio

Table 46 AstraZeneca : Key Developments

Table 47 Viatris Inc: Overview

Table 48 Viatris Inc: Product Portfolio

Table 49 Viatris Inc: Key Developments

Table 50 Teva Pharmaceutical Industries Ltd: Overview

Table 51 Teva Pharmaceutical Industries Ltd: Product Portfolio

Table 52 Teva Pharmaceutical Industries Ltd: Key Developments

Table 53 BASF SE: Overview

Table 54 BASF SE: Product Portfolio

Table 55 BASF SE: Key Developments

Table 56 Dr Reddy's Laboratories Ltd: Overview

Table 57 Dr Reddy's Laboratories Ltd: Product Portfolio

Table 58 Dr Reddy's Laboratories Ltd: Key Developments

Table 59 Merck & Co Inc: Overview

Table 60 Merck & Co Inc: Product Portfolio

Table 61 Merck & Co Inc: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Synthetic API Market Value, 2022-2031 (US$ Million)

Figure 2 Global Synthetic API Market Share, By Type, 2023 & 2031 (%)

Figure 3 Global Synthetic API Market Share, By Manufracturer Type, 2023 & 2031 (%)

Figure 4 Global Synthetic API Market Share, By Application, 2023 & 2031 (%)

Figure 5 Global Synthetic API Market Share, By Region, 2023 & 2031 (%)

Figure 6 Global Synthetic API Market Y-o-Y Growth, By Type, 2023-2031 (%)

Figure 7 Innovative Synthetic API Synthetic API Market Value, 2022-2031 (US$ Million)

Figure 8 Generic Synthetic API Synthetic API Market Value, 2022-2031 (US$ Million)

Figure 9 Global Synthetic API Market Y-o-Y Growth, By Manufracturer Type, 2023-2031 (%)

Figure 10 Captive API Manufacturer Manufracturer Type in Global Synthetic API Market Value, 2022-2031 (US$ Million)

Figure 11 Merchant API Manufacturer Manufracturer Type in Global Synthetic API Market Value, 2022-2031 (US$ Million)

Figure 12 Global Synthetic API Market Y-o-Y Growth, By Application, 2023-2031 (%)

Figure 13 Cardiology  Application in Global Synthetic API Market Value, 2022-2031 (US$ Million)

Figure 14 Pulmonology  Application in Global Synthetic API Market Value, 2022-2031 (US$ Million)

Figure 15 Oncology  Application in Global Synthetic API Market Value, 2022-2031 (US$ Million)

Figure 16 Ophthalmology Application in Global Synthetic API Market Value, 2022-2031 (US$ Million)

Figure 17 Neurology  Application in Global Synthetic API Market Value, 2022-2031 (US$ Million)

Figure 18 Orthopedic  Application in Global Synthetic API Market Value, 2022-2031 (US$ Million)

Figure 19 Other Application in Global Synthetic API Market Value, 2022-2031 (US$ Million)

Figure 20 Global Synthetic API Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 21 North America Synthetic API Market Value, 2022-2031 (US$ Million)

Figure 22 Asia-Pacific Synthetic API Market Value, 2022-2031 (US$ Million)

Figure 23 Europe Synthetic API Market Value, 2022-2031 (US$ Million)

Figure 24 South America Synthetic API Market Value, 2022-2031 (US$ Million)

Figure 25 Middle East and Africa Synthetic API Market Value, 2022-2031 (US$ Million)

Figure 26 North America Synthetic API Market Value, 2022-2031 (US$ Million)

Figure 27 North America Synthetic API Market Share, By Type, 2023 & 2031 (%)

Figure 28 North America Synthetic API Market Share, By Manufracturer Type, 2023 & 2031 (%)

Figure 29 North America Synthetic API Market Share, By Application, 2023 & 2031 (%)

Figure 30 North America Synthetic API Market Share, By Country, 2023 & 2031 (%)

Figure 31 South America Synthetic API Market Value, 2022-2031 (US$ Million)

Figure 32 South America Synthetic API Market Share, By Type, 2023 & 2031 (%)

Figure 33 South America Synthetic API Market Share, By Manufracturer Type, 2023 & 2031 (%)

Figure 34 South America Synthetic API Market Share, By Application, 2023 & 2031 (%)

Figure 35 South America Synthetic API Market Share, By Country, 2023 & 2031 (%)

Figure 36 Europe Synthetic API Market Value, 2022-2031 (US$ Million)

Figure 37 Europe Synthetic API Market Share, By Type, 2023 & 2031 (%)

Figure 38 Europe Synthetic API Market Share, By Manufracturer Type, 2023 & 2031 (%)

Figure 39 Europe Synthetic API Market Share, By Application, 2023 & 2031 (%)

Figure 40 Europe Synthetic API Market Share, By Country, 2023 & 2031 (%)

Figure 41 Asia-Pacific Synthetic API Market Value, 2022-2031 (US$ Million)

Figure 42 Asia-Pacific Synthetic API Market Share, By Type, 2023 & 2031 (%)

Figure 43 Asia-Pacific Synthetic API Market Share, By Manufracturer Type, 2023 & 2031 (%)

Figure 44 Asia-Pacific Synthetic API Market Share, By Application, 2023 & 2031 (%)

Figure 45 Asia-Pacific Synthetic API Market Share, By Country, 2023 & 2031 (%)

Figure 46 Middle East & Africa Synthetic API Market Value, 2022-2031 (US$ Million)

Figure 47 Middle East & Africa Synthetic API Market Share, By Type, 2023 & 2031 (%)

Figure 48 Middle East & Africa Synthetic API Market Share, By Manufracturer Type, 2023 & 2031 (%)

Figure 49 Middle East & Africa Synthetic API Market Share, By Application, 2023 & 2031 (%)

Figure 50 Pfizer Inc.: Financials

Figure 51 Sanofi SA: Financials

Figure 52 Boehringer Ingelheim: Financials

Figure 53 Bristol-Myers Squibb: Financials

Figure 54 AstraZeneca : Financials

Figure 55 Viatris Inc: Financials

Figure 56 Teva Pharmaceutical Industries Ltd: Financials

Figure 57 BASF SE: Financials

Figure 58 Dr Reddy's Laboratories Ltd: Financials

Figure 59 Merck & Co Inc: Financials